Engineers Gate Manager LP Immunovant, Inc. Transaction History

Engineers Gate Manager LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$25.1 - $31.61 $340,456 - $428,758	13,564 New	13,564 $358,000
Q4 2023 Feb 14, 2024	BUY	$31.31 - $44.19 $264,600 - $373,449	8,451 New	8,451 $356,000
Q2 2023 Aug 14, 2023	BUY	$14.2 - $23.75 $376,569 - $629,826	26,519 New	26,519 $503,000
Q2 2022 Aug 15, 2022	SELL	$3.38 - $5.65 $48,334 - $80,795	-14,300 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$5.06 - $8.77 $2,869 - $4,972	567 Added 4.13%	14,300 $79,000
Q4 2021 Feb 14, 2022	BUY	$7.33 - $9.32 $100,662 - $127,991	13,733 New	13,733 $117,000

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.